Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | AGXT | P21549 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166513 | 0.78 | KMT2A (0.50) | RECQLNUDT1KMT2A | |
| SCHEMBL9918974 | 0.77 | LMNA (0.38) | RECQLNUDT1POLBHTTKMT2A | |
| SCHEMBL8888 | 0.76 | QPCT (0.40) | RECQLNUDT1HTTKMT2AGAA | |
| SCHEMBL1996295 | 0.74 | ALDH1A1 (0.44) | RECQLNUDT1POLBHTTKMT2A | |
| SCHEMBL31631823 | 0.74 | NUDT1 (0.59) | NUDT1KMT2A | |
| SCHEMBL24225498 | 0.74 | NUDT1 (0.34) | RECQLNUDT1POLBHTTKMT2A | |
| SCHEMBL4055116 | 0.74 | NUDT1 (0.34) | RECQLNUDT1POLBHTTKMT2A | |
| SCHEMBL4055122 | 0.74 | NUDT1 (0.59) | NUDT1KMT2A | |
| SCHEMBL19145049 | 0.74 | RECQL (0.43) | RECQLNUDT1POLBKMT2AGAA | |
| SCHEMBL18791323 | 0.72 | ELANE (0.37) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | RECQL 2479/4885NUDT1 2234/4885POLB 3818/4885 |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | RECQL 1796/4885NUDT1 3111/4885POLB 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.